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Available online xxxxDuring the course of a toxic challenge, changes in gene expression can manifest such as induction of metabolizing en-
zymes as a compensatory detoxification response.We currently report that a single 400mg/kg acetaminophen (APAP)
dose to C57BL/6J mice led to an increase in multidrug resistance-associated (Mrp) 4 (Abcc4) mRNA 12 h after admin-
istration. Alanine aminotransferase, as a marker of liver injury, was also elevated indicating hepatotoxicity had oc-
curred. Therefore, induction of Mrp4 mRNA was likely attributable to APAP-induced liver injury. Mrp4 has been
shown to be upregulated during oxidative stress, and it is well-established that APAP overdose causes oxidative stress
due to depletion of glutathione. Given the importance ofMrp4 upregulation as an adaptive response during cholestatic
and oxidative liver injury, we next investigated the extent by which human MRP4 can be inhibited by the analgesics,
APAP, diclofenac (DCF), and their metabolites. Using an in vitro assay with inside out humanMRP4 vesicles, we deter-
mined that APAP-cysteine inhibited MRP4-mediated transport of leukotriene C4 with an apparent IC50 of 125 μM.
APAP-glutathione also attenuated MRP4 activity though it achieved only 28% inhibition at 300 μM. Diclofenac acyl
glucuronide (DCF-AG) inhibited MRP4 transport by 34% at 300 μM. The MRP4 in vitro inhibition occurs at APAP-
cysteine and DCF-AG concentrations seen in vivo after toxic doses of APAP or DCF in mice, hence the findings are im-
portant given the role that Mrp4 serves as a compensatory response during oxidative stress following toxic challenge.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Injury following overdose with analgesics is relatively common and can
result in extensive damage to multiple organs that may ultimately lead to
death in severe cases (Jones, 2002). Mild to moderate toxicity may induce
changes vis-à-vis regulation of genes. Such changes involve modulation of
transcription factors or induction of drug transporters as a compensatory re-
sponse (Blazka et al., 1995; Barnes et al., 2007). Intoxication with acet-
aminophen (APAP), for example, has been demonstrated to result in
upregulation of the efflux transporter multidrug resistance-associated pro-
tein (Mrp) 4 as well as the metabolic enzyme flavin containingnosine monophosphate; APAP, acetam
inophen sulfate; ATP, adenosine tri
; MRP, multidrug resistance-associated
t. of Pharmaceutical Sciences, 69 Nort
tou).
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ier B.V. This is an open access articmonooxygenase (Fmo) 3, a particularly novel finding given that Fmo3
was previously thought to be non-inducible (Campion et al., 2008;
Rudraiah et al., 2014a; Cashman and Zhang, 2002). The mechanism of
Mrp4 induction has been demonstrated to be linked to activation of nuclear
factor erythroid 2-like 2 (Nrf2, Nfe2l2) as evidenced by lack of Mrp4 upreg-
ulation in Nrf2 knockout mice (Ghanem et al., 2015). Furthermore, Mrp4
induction by APAP was found to be dependent on Kupffer cell activation
(Campion et al., 2008). Mrp4 expression also was induced after administra-
tion of clofibrate via activation of peroxisome proliferator-activated recep-
tor α (Moffit et al., 2006). In a mouse model, the elevated expression of
Mrp4 after an initial toxic APAP insult results in mice becoming refractoryinophen; APAP-CYS, acetaminophen cysteine; APAP-GLU, acetaminophen glucuronide; APAP-
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(Aleksunes et al., 2008a).
In the previously cited work by Campion and colleagues, protein induc-
tion became evident two to three days after administration of toxic doses of
APAP (Campion et al., 2008). Measurement of ALT as an indicator of hepa-
tocellular injury has been utilized in human and rodents, and there is a clear
relationship between ALT and manifestations of hepatic injury (Singhal
et al., 2012; McGill et al., 2012). Furthermore, Rudraiah et al. (2014b) re-
ported elevations in ALT and Fmo3 mRNA following toxic APAP treatment
leading the authors to conclude that induction of Fmo3 was likely a protec-
tive mechanism in response to APAP-induced hepatotoxicity. To date,
transporter expression as a function of changes in ALT has not been thor-
oughly investigated.
As expected, administration of xenobiotics results in the generation of
metabolites that can be eliminated through biliary or urinary excretion.
Work from our group has previously shown that metabolites of APAP and
diclofenac (DCF) (Fig. 1) can be generated in high concentrations, with re-
spect to the parent compound, after administration of toxic doses (Scialis
et al., 2015; Manautou et al., 2005; Chen et al., 2003). Though metabolite
disposition has been characterized, and in some instances the affinity for
an uptake or efflux transporter to mediate metabolite clearance quantified
(Zamek-Gliszczynski et al., 2006; Zelcer et al., 2003; Scialis and Manautou,
2016; Scialis et al., 2019), there has not been systematic examination as to
the potential for these metabolites to interfere with normal transporter
function. Despite the extensive pharmacokinetic and toxicological investi-
gations on APAP and DCF as well as characterizations on their metabolites
(such as metabolizing enzymes, formation rates, reactivities, etc.), there is
still a lack of knowledge on how metabolites of these two importantFig. 1. Structures of APAP, DCF, and their major metabolites. The various conjugated m
the CYP450-mediated reactive intermediate NAPQI. APAP: acetaminophen, APAP-CY
acetaminophen glutathione, APAP-NAC: acetaminophen N-acetylcysteine, APAP-SUL:
AG: diclofenac acyl glucuronide.
35analgesics can perturb critical cellular functions. Considering the impor-
tance MRP4 serves as a compensatory response following toxicant chal-
lenge, it is crucial to understand the nature of MRP4 activity in the
presence of metabolites at concentrations that are known to occur in vivo.
The work presented herein addresses the aforementioned knowledge gap
and represents hitherto unreported findings as it relates to MRP4 function.
Thus, the primary objective of our current work was to first assess the
relationship, if one exists, between elevations in ALT and transcriptional
regulation of Mrp4. To accomplish this goal, a toxic dose of APAP was
given toC57BL/6Jmicewithmeasurement of ALT andMrp4mRNA carried
out at several time points post-administration. The secondary objective of
our inquiry focuses on the inhibition of MRP4 by APAP, DCF, and their pri-
marymetabolites. This objective was deemed relevant to better understand
how MRP4 activity, following its induction after toxic challenge, could be
modulated by physiological levels of xenobiotics and their derivatives.
The MRP4 inhibition assays were conducted using APAP and DCF metabo-
lite concentrations that reflect those observed during in vivo studies from
our laboratory.
2. Materials and methods
2.1. Chemicals and reagents
APAP, AMP, ATP, DCF, formic acid, indomethacin (used as the internal
standard, IS), KCl, MgCl2, MOPS, 4′-hydroxy diclofenac (OH-DCF), and
Tris-HCl, were purchased from Sigma-Aldrich Corporation. (St. Louis,
MO). Diclofenac acyl glucuronide (DCF-AG) was purchased from Toronto
Research Chemicals Incorporated (Toronto, Canada). Acetominophenetabolites of APAP as the result of Phase II metabolism or spontaneous adduction to
S: acetaminophen cysteine, APAP-GLU: acetaminophen glucuronide, APAP-GSH:
acetaminophen sulfate, DCF: diclofenac, 4′-OH-DCF: 4′-hydroxy diclofenac, DCF-
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acetominophen glutathione (APAP-GSH), acetominophen N-
acetylcysteine (APAP-NAC), and acetominophen sulfate (APAP-SUL) were
obtained from McNeil-PPC Incorporated (Fort Washington, PA). Leukotri-
ene C4 (LTC4) andMK-571were purchased from Santa Cruz Biotechnology
(Dallas, TX). MRP4 vesicles were purchased fromGenoMembrane Corpora-
tion (Kanazawa, Japan). All LC-MS/MS solvents were of high analytical
grade and were purchased from Burdick & Jackson (Muskegon, MI).
2.2. Animal studies
Male C57BL/6J mice were purchased from Jackson Laboratories (Bar
Harbor, ME). Mice were housed in an American Animal Associations Labo-
ratory Animal Care accredited facility at the University of Connecticut
under a standard temperature-, light-, and humidity-controlled environ-
ment. Mice had free access to Harlan Teklad 2018 chow (Harlan, Madison,
WI) and drinkingwater.Mice, aged 2–3months, received a single IP dose of
400mg/kg APAP in 0.9% saline andwere sacrificed by decapitation at 0, 6,
12, and 24 h after APAP administration. Blood samples were collected and
subsequently centrifuged at 1200 ×g for 15 min to yield plasma. Livers
were harvested, rinsed in ice-cold saline, and quickly frozen in liquid nitro-
gen prior to storage at −80 °C. Untreated 2 month male mice C57BL/6J
mice were sacrificed by decapitation for liver harvesting. Livers were
quickly harvested, rinsed with phosphate buffer, and snap-frozen in liquid
nitrogen. All animal studies were performed in accordance with the Na-
tional Institutes of Health Guide for the Care and Use of Laboratory Animals
using protocols reviewed and approved by the local Institutional Animal
Care and Use Committee at the University of Connecticut.
2.3. Transporter expression
Isolation of RNA and mRNA quantification for major hepatic trans-
porters were conducted as previously reported (Campion et al., 2009).
Briefly, RNA was extracted using RNA Bee reagent (Tel-Test, Friendswood,
TX), pooled, and quantified with branched DNA (bDNA) method using a
QuantiGene® Screen Assay Kit (Panomics, Freemont, CA) following the
manufacturer's respective protocols. Probes against mouse uptake Oatps
and Ntcp transporters and mouse Mrps and Mdr1 efflux transporters were
utilized. Transporter expression was expressed as relative light units
(RLU) per 10 μg of RNA.
2.4. RNA isolation and RT-PCR
Total liver RNA was extracted using TRIzol reagent (Thermo Fisher Sci-
entific, Waltham, MA) according to the manufacturer's protocol. The con-
centration of total RNA in each sample was quantified
spectrophotometrically at 260 nm, and the integrity was evaluated by aga-
rose gel electrophoresis. RNA (1 μg) was reverse transcribed to cDNA using
an M-MLV Reverse Transcriptase kit (Thermo Fisher Scientific). mRNA ex-
pression of Abcc4 was quantified using specific primers (Table 1) by the
ΔΔCT method and normalized to the housekeeping gene Actb. Primer
pairs were synthesized by Integrated DNA Technologies (Coralville, IA).
Amplification was performed using an Applied Biosystems 7500 Fast
Real-Time PCR System (Thermo Fisher Scientific) and carried out in a 20Table 1
Primer sequences for quantitative RT-PCR.
Gene (protein) Primer sequence
Actb (β-actin) Forward: 5′-GCA ACG AGC GGT TCCG-3′
Reverse: 5′-GCA GAC AGC CAA GGA GCC CAA AGA CC-3′
Abcc4 (Mrp4) Forward: 5′-ACC TCT GCT CGC GCG TGT TCT-3′
Reverse: 5′-CCA GTA CCG TTG AAG CTC CTC TCC-3′
36μL reaction volume containing diluted cDNA, Fast SYBR Green PCRMaster
Mix (Thermo Fisher Scientific), and 1 μM of each primer.2.5. Clinical chemistry
Plasma samples were analyzed for alanine aminotransferase (ALT)
using a kit purchased from Thermo Fisher Scientific as per the manufactur-
er's recommendations. A BioTek UV/Vis microplate spectrophotometer
(BioTek Instruments Incorporated, Winooski, VT) was used to measure
assay endpoints.2.6. In vitro transport
Commercially available MRP4 inside-out vesicles from GenoMembrane
were quickly thawed from storage and placed on ice. Incubation reactions
consisted of uptake buffer at pH 7.0 (50 mM MOPS-Tris, 70 mM KCl, and
7.5 mM MgCl2), 25 μg vesicle protein, 5 mM of AMP or ATP, and 2.5 mM
GSH. After a 5 min pre-incubation period of reaction mixture, incubations
were commenced by addition of increasing concentrations of LTC4 for sub-
strate studies. For inhibition studies, the concentration of LTC4 was fixed
while increasing concentrations of inhibitor was added. Incubations were
conducted at 37 °C in a total volume of 75 μL. Reactions were quenched
by the addition of 100 μL ice-cold stopping buffer (40 mMMOPS-Tris and
70 mM KCl), and the quenched mixtures were quickly transferred to a 96-
well glass-fiber filter plate (EMD Millipore, Billerica, MA). The plate was
subjected to vacuum filtration followed by 5 rapid washes of 100 μL/well
ice-cold stopping buffer. The filter plate was allowed to dry before extrac-
tion of samples. Once the filter plate was dry, LTC4 was extracted by filling
each well of the filter plate with 200 μL of 80:20 (v/v) methanol: water.
Plates were shaken for 15 min on ice, and the filtrate was collected via cen-
trifugation at 3000 ×g for 10 min and 4 °C. The filtrate was evaporated to
dryness under warm N2 at 40 °C. The resulting residue was reconstituted
with 100 μL water and 100 μL IS in methanol, vigorously vortex-mixed,
and injected onto the LC-MS/MS. The accumulation of LTC4 was quantified
against a standard curve, and the data were expressed as pmol uptake nor-
malized to mg vesicle protein.2.7. LC-MS/MS method
Chromatographic separation of analytes was performed on a 2.6 μm
Kinetex XB-C18 30 × 2 mm column (Phenomenex Incorporated, Tor-
rance, CA). The system front end consisted of a HTC PAL Autosampler
(LEAP Technologies Incorporated, Carrboro, NC), a CBM-20A system
controller, two LC20ADvp pumps, and a DGU-14A degasser (Shimadzu
Scientific Instruments, Columbia, MD). Analytes of interest were eluted
using a gradient program that began with 10% solvent B for the first
0.5 min, which was then increased to 90% solvent B at 1.25 min using
a linear gradient and held at this mixture for 0.25 min before reverting
back to initial solvent conditions for 0.5 min to re-equilibrate the col-
umn. The flow rate for was 0.3 mL/min, and the column effluent was di-
rected to waste for the initial 0.5 min before switching to the mass
spectrometer. Analytes were detected using an AB Sciex API™ 4000
LC-MS/MS triple quad mass-spectrometer with a TurboIonSpray®
probe and Analyst version 1.5.2 software (AB Sciex, Framingham, MA)
that was operated in multiple reaction monitoring mode. Ion spray volt-
age was −4250 V, and the source temperature was set to 400 °C. The
mass transitions in negative ion mode for monitoring LTC4 and IS
were m/z 626.4 → 189.5 and 356.0 → 311.8, respectively. The reten-
tion times of LTC4 and IS were 1.33 and 1.47 min, respectively. Concen-
trations of analytes in the samples were determined by comparing the
peak area ratios (analyte/IS) to those in the standard curve using a lin-
ear regression model. The criterion of acceptance for standards was de-
fined to be ±20% of nominal concentration.
Fig. 2. Transporter expression in C57BL/6J malemouse liver. The basal transporter
expression in the livers of naïve male C57BL/6J mice is shown. Expression profiles
were detected using a bDNA assay. Data are expressed as relative light units (RLU)
per 10 μg RNA. Each bar reflects the mean ± standard error of the mean of n = 4
subjects. *P < 0.05 versus all other groups.
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Where IC50 estimates could be determined for Mrp4 inhibition, Ki
values for the inhibitors were calculated according to the following equa-





where Ki is the affinity of the inhibitor, IC50 is the inhibitor concentration
producing 50% inhibition, [S] is the substrate concentration in the incuba-
tion, and Km is theMichaelis constant representing substrate affinity for the
transporter.
2.9. Statistical analysis
Data are expressed as mean ± standard error of the mean. P values≤
0.05 were considered as statistically significant. Statistical analysis of data
was performed using R version 3.5.3 (R Core Team, 2015). Two groups
were compared by Student's t-test, and multiple groups were compared
by an analysis of variance followed by Tukey's post hoc test. GraphPad
Prism version 6.0 (GraphPad Software Incorporated, La Jolla, CA) was
used to calculate kinetic parameters (Vmax and Km) as well as the IC50 inhi-
bition parameter.Fig. 3. Relationship between ALT values and Mrp4 gene expression following acute e
sacrificed 0, 6, 12, or 24 h after administration. A) ALT was determined from plasma.
B) Mrp4 mRNA expression was determined via RT-PCR using RNA extracted from who
for n = 5–7 subjects/group. *P < 0.05 versus all other groups.
373. Results
3.1. Basal transporter expression
Livers from naïve C57BL/6J male mice were harvested and assessed for
transporter expression using a bDNA assay. The liver specific uptake trans-
porter Oatp1b2 (Slco1b2) had the highest transcriptional expression of all
the transporters investigated (Fig. 2). After Oatp1b2, Oatp1a1 (Slco1a1)
and Ntcp (Slco10a1) had the second and third highest expression, respec-
tively, for uptake transporters. In terms of efflux transporters, Mrp2
(Abcc2), which is expressed at the bile canaliculi, was highest while also
being the third most abundant of all transporters. The basolateral trans-
porters of Mrp3 (Abcc3) and Mrp6 (Abcc6) constituted the second and
third most abundant of the efflux transporters. The expression of the six
aforementioned transporters was statistically significant compared to
each other (P < 0.05). Mrp4, along with Mrp1 (Abcc1) and Mdr1a
(Abcb1a), had among the lowest basal hepatic transporter expression.
3.2. In vivo study
C57BL/6J male mice were administered a single IP dose of 400 mg/kg
APAP in 0.9% saline. Animals were sacrificed 0, 6, 12, and 24 h post admin-
istration, and livers were harvested. Plasma was used to assess liver injury
using ALT as a marker. The mean ALT values at 0, 6, 12, and 24 h were
41.4, 1140, 760, and 2400 U/L, respectively (Fig. 3A). Transcriptional
changes of Mrp4 were assessed at the same time points used for ALT anal-
ysis (Fig. 3B). An increase in Mrp4 mRNA was only observed at 12 h, how-
ever this increase was statistically significant (P < 0.05). Taken together,
the data suggest that APAP-induced liver injury, evidenced by high ALT
values, resulted in the induction of Mrp4 mRNA.
3.3. LTC4 kinetics
Human MRP4 was characterized for transport of LTC4 prior to
conducting inhibition studies. The linearity of MRP4-mediated transport
for 0.1 μM LTC4 was evaluated and determined to be time-dependent
(Fig. 4A). The dynamic response reached a maximal value of 19-fold
(ATP response divided by AMP response) by 20 min. Next, LTC4 was char-
acterized for concentration-dependent transport. Kinetic parameters of
Vmax and Km for MRP4 LTC4 transport were determined to be 245
pmol/min/mg and 4.25 μM, respectively (Fig. 4B). Kinetic data were fitted
using a single Km model without assuming cooperativity.
3.4. MRP4 inhibition
The potential for MRP4 inhibition was carried out in the presence of
parent compounds and their metabolites. MK-571 was used as an inhibitorxposure to APAP. Male C57BL/6J mice were administered 400 mg/kg APAP and
The horizontal dotted line reflects the ALT upper limit of normal value of 40 U/L.
le liver homogenate. Data are expressed as the mean ± standard error of the mean
R.J. Scialis et al. Current Research in Toxicology 1 (2020) 34–41control yielding an IC50 of 14.2 μM (Fig. 5), a value that is close to its re-
ported IC50 against other probes (Reid et al., 2003a; Rius et al., 2003).
APAP-CYS inhibited transport with an IC50 of 125 μM. As only MK-571
and APAP-CYS could be fitted to yield IC50 values, none of the other com-
pounds are shown with fitted lines. APAP, APAP-GLU, APAP-NAC, and
APAP-SUL did not manifest any significant inhibition. APAP-GSH de-
creased MRP4 transport, but only at the two highest concentrations
resulting in 29% inhibition at 300 μM. DCF and its metabolites likewise
inhibited MRP4, with DCF-AG showing the greatest inhibition reaching a
maximal inhibition of 34% at the highest tested concentration of 300 μM.
The apparent Ki values using Eq. (1) for MK-571 and APAP-CYSwere calcu-
lated to be 13.9 and 122 μM, respectively.
4. Discussion
The objective of our current work was to evaluate the regulation and
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Fig. 4. Time-dependent and concentration-dependent transporter kinetics of LTC4
with MRP4 vesicles. MRP4 vesicles were incubated with LTC4 in the presence of
either AMP or ATP. (A) The time-dependent transport of 0.1 μM LTC4 in the
presence of 5 mM AMP (○) or 5 mM ATP (●) at 37 °C. The dotted line represents
the nonlinear fit of LTC4 active transport and was calculated by subtracting the
AMP values (background and passive uptake) from the ATP response. (B) The
concentration-dependent transport of LTC4 at 37 °C. The fitted line indicates the
ATP-dependent transport assuming typical Michaelis-Menten kinetics. Inset:
Eadie-Hofstee plot. Each data point reflects the mean ± the standard error of the
mean for n = 3 measurements per time point or concentration.
38hepatic transporters in untreated C57BL/6J mouse livers showed that
Mrp4 has one of the lowest expression levels in a comparative profile
panel of uptake and efflux transporters. These data are comparable to the
observations for C57BL/6J mice reported by Slitt et al. and Aleksunes
et al. who independently demonstrated Oatp1b2 and Oatp1a1 have the
highest and second highest basal expression for hepatic uptake transporters
whileMrp2 andMrp3dominate efflux transporter expression relative to the
other Mrps (Slitt et al., 2007; Aleksunes et al., 2005). The present work is
advantageous in that it provides the reader a more thorough assessment
of basal hepatic transporter expression in naive mouse liver. Despite its
seemingly low hepatic expression during homeostatic conditions, Mrp4 is
quite inducible and plays a major role after intoxication by xenobiotics.
As an example, work by Campion et al. (2008) showed that among the
Mrp class of transporters, Mrp4 was the most inducible after a 500 mg/kg
IP APAP dose to C57BL/6J mice, and its protein expression increased 10-
and 33-fold by 48 and 72 h, respectively. Furthermore, the mechanism of
induction was shown to be dependent on the functional presence of hepatic
macrophages known as Kupffer cells. Loss of Kupffer cell viability, via
targeted cell death by the agent clodronate, resulted in loss of Mrp4 induc-
tion. Moreover, induction of Mrp4 following APAP challenge was also
found to be dependent on the activation of transcription factor Nrf2, as
mice lacking Nrf2 did not show any changes to Mrp4 mRNA or protein
levels in response to APAP (Aleksunes et al., 2008b). During the course of
our current study, we observed that Mrp4 mRNA was significantly upregu-
lated 12 h,with respect toMrp4RNAat 6 and 24 h, after a 400mg/kgAPAP
challenge. Curiously, the Mrp4 mRNA levels were essentially the same at 6
and 24 h suggesting that Mrp4 transcriptional activation may be transient.
However, given the prior protein expression data, we postulate that the
transcriptional upregulation at 12 h was sufficient to be the driving factor
for Mrp4 protein levels to reach maximal expression at 48 h.
We next sought to draw correlation between liver injury and Mrp4
mRNA. Serum ALT has been used a reliable indicator for liver injury, and
we detected ALT levels that were consistent with APAP toxicity. ALT levels
were elevated by nearly 20-fold or greater compared to the upper limit of
normal at all the time points examined, while Mrp4 mRNA reached maxi-
mal induction 12 h post-dose. None of the other hepatic Abc transporters
showed any significant increase compared to control following APAP ad-
ministration (data not shown) suggesting that only Mrp4 induction occurs
as a result of APAP toxic challenge. Ghanem et al. (2015) similarly reported
that ALT and Mrp4 mRNA levels in mouse brain were significantly in-
creased 24 h following toxic challenge by APAP. The sustained ALT in the
current study from 6 to 24 h was a clear indication that liver injury was
notmerely a transient occurrence. Indeed, Rudraiah et al. (2014b) observed
an association between ALT and flavin containing monooxygenase-3
(Fmo3) mRNA where both reached maximal values 48 h after a 400 mg
APAP dose. Despite the fact that ALT and Mrp4 mRNA induction were
not correlative across all three measured time points, the results suggest
that liver injury following toxic APAP administration, as evidenced by
high ALT levels, may have acted as trigger for the induction of Mrp4
mRNA. Interestedly, though it has been shown that perturbation of Mrp4
induction led to increased toxicity after APAP challenge, a recent study
demonstrated that wild-type and Mrp4-null mice were equally susceptible
to APAP-induced hepatotoxicity at the same 400 mg/kg dose used in the
current study (Donepudi et al., 2019). However, it should be noted that
Mrp4-null mice have decreased expression of Phase I enzymes involved in
APAP metabolism, hence the injury parity between WT and Mrp4-null
mice may have been due to decreased generation of reactive metabolites
in theMrp4-null mice. Lastly, themaximalMrp4mRNA induction observed
at 12 h mimics that observed by Campion et al. (2009) who reported that
both Mrp3 and Mrp4 mRNA peaked at 12 h before returning to baseline
from24 to 72 h following toxic challenge to allyl alcohol and that the induc-
tion led to increased protein expression of both efflux transporters. For fur-
ther insight on Mrp3 induction after xenobiotic exposure, the reader is
directed to a recent review by Ghanem and Manautou (2019).
Given the importanceMrp4 has as an apparent compensatory protective
response during APAP toxicity, we investigated the potential for Mrp4
Fig. 5. Inhibition of MRP4 activity by APAP, APAP metabolites, DCF, and DCF metabolites. In vitro inhibition was conducted using MRP4 vesicles with 0.1 μM LTC4 in the
presence of 5 mMATP at 37 °C for 5 min. The ATP-dependent transport of LTC4 in the absence of inhibitor was set to 100%. Inhibition data were fit with a three parameter
model to calculate IC50. Dotted lines reflect the 95% confidence intervals of the fit. Only compounds achieving >50% inhibition were fitted. Each data point reflects
individual values (n = 2 per inhibitor concentration).
R.J. Scialis et al. Current Research in Toxicology 1 (2020) 34–41inhibition by the analgesics APAP, DCF, and their metabolites. The ratio-
nale for investigating Mrp4 inhibition is based on the finding that Mrp4 is
upregulated as a compensatory mechanism during oxidative stress (Xu
et al., 2010). Considering APAP and DCF metabolism can cause oxidative
stress that can lead to hepatotoxicity (Lauer et al., 2009; Gao et al.,
2017), inhibition of Mrp4 by APAP or its metabolites may further39exacerbate liver injury and/or hamper tissue recovery. In lieu of mouse
Mrp4, we chose to use vesicles containing human MRP4 as a surrogate.
Our first course of action was to characterize the assay for performance.
Among the substrates forMRP4 are estradiol-17β-glucuronide, furosemide,
and methotrexate (Chen et al., 2001; Chen et al., 2002; Hasegawa et al.,
2007). The choice of estradiol-17β-glucuronide as a probe can result in
R.J. Scialis et al. Current Research in Toxicology 1 (2020) 34–41potentially misleading findings as it was shown to be stimulated by numer-
ous compounds that were able to inhibit the vesicular transport for other
substrates (Kidron et al., 2012; Gilibili et al., 2017). Hence, we decided to
use Leukotriene C4 as our probe based on the work of Rius et al. (Rius
et al., 2008) that identified LTC4 as a substrate forMRP4. LTC4 as ameasure
of MRP4 activity is advantageous since it is a naturally occurring derivative
of arachidonic acid and plays a role during pro-inflammatory responses
(Dahlen et al., 1983; Zipser et al., 1987). Using inside-out MRP4 vesicles,
we determined that the transport of LTC4 was time-dependent. Further-
more, the transport of LTC4 was concentration-dependent with a Vmax
and Km of 253 pmol/min/mg and 4.25 μM, respectively.
We next proceeded to conduct MRP4 inhibition assays, and expanded
our assay to include the analgesics APAP andDCF aswell as theirmajorme-
tabolites. Our results show that APAP has no effect on MRP4, and neither
did APAP-SUL, APAP-GLU, or APAP-NAC. However, we observed that
APAP-CYS had concentration-dependent inhibition ofMRP4with an appar-
ent IC50 of 125 μM. Based on the in vitro parameters from our assays, we cal-
culate a Ki of 122 μM for APAP-CYS. Bearing inmind the low LTC4 substrate
concentration relative to its Km and ratio of IC50 to Ki, it is likely the inhibi-
tion of MRP4 by APAP-CYS was of a competitive nature (Burlingham and
Widlanski, 2003). This is perhaps suggestive that APAP-CYS may be a sub-
strate of MRP4 rather than an allosteric modulator of transporter activity.
Indeed, cysteine derivatives have previously been shown to be transporter
substrates. For example, N-acetylcysteine (NAC) and cisplatin N-
acetylcysteine conjugate were separately determined to be substrates for
human organic anion transporters (OAT) 1 and 3, however NAC was
found to be negative for MRP 1- and 4-mediated transport (Hagos et al.,
2017; Hu et al., 2017). That APAP-NAC did not manifest inhibitionwas sur-
prising considering the structural resemblance it shares with APAP-CYS.
Yet, APAP-GSH, which has a longer side chain compared to APAP-NAC
and would potentially have greater steric hindrance, was able to inhibit
LTC4 transport by 29% at 300 μM. The inhibition by APAP-GSH may also
have been due to competitive transport as it has been shown that glutathi-
one itself is a substrate for MRP4 when tested at millimolar concentrations
(Rius et al., 2003; Rius et al., 2006). The results show the high specificity
and discretionary recognition by MRP4 of closely related chemical entities.
Inhibition by APAP-GSH is intriguing in light of the fact that it is a major
metabolite stemming from sequestration of the highly reactive APAP inter-
mediateN-acetyl-p-benzoquinone imine (Moore et al., 1985;Mitchell et al.,
1973).
A limitation of our study was that we were not able to measure either
APAP-CYS or APAP-GSH MRP4-mediated transport due to limited metabo-
lite supply. Follow-up investigation should be conducted to determine if
APAP-CYS and APAP-GSH can in fact be transported by MRP4. Overall
the results demonstrate that although metabolism can generally be
regarded as a detoxification pathway, subsequent metabolites may possess
untoward inhibitory potency against mechanisms, such as transporters,
that would normally expedite elimination of said toxicants or reactive inter-
mediates. Thus within the realm of discovery toxicology for compounds in
preclinical development, it will be important to not only ascertain up- or
down-regulation of important clearance mechanisms, but to also determine
the extent by which these mechanisms may be impacted by either parent
and/or metabolites present at the site of interest. This statement is
underscored by the novel finding of MRP4 inhibition by APAP metabolites
that were tested at concentrations known to occur following high dose
APAP administration.
The interest in DCF as an MRP4 inhibitor comes from numerous ob-
servations that DCF, similar to APAP, generates reactive metabolites
that may act as contributors to drug-induced liver injury following re-
peated DCF exposure. Akin to APAP-GSH, DCF and two of its main me-
tabolites produced inhibition of MRP4, with DCF-AG achieving 34%
inhibition. The DCF inhibition was not surprising as a previous investi-
gation established that DCF was able to inhibit the MRP4-mediated up-
take of methotrexate (El-Sheikh et al., 2007). In that study, DCF was
found to possess a two-site affinity with IC50 values of 326 and 0.006
μM for the high and low affinity site, respectively. Since DCF only40achieved 22% for the current study, the difference in potency is likely
reflective of substrate selection. MRP4 inhibition by DCF parent and me-
tabolites may have physiological ramifications. Studies point to MRP4
being an efflux transporter for prostaglandin E2 (PGE2) (Reid et al.,
2003b), which like LTC4 is also derived from arachidonic acid. In
light of PGE2's role in promoting cell survival and repair (Takeuchi,
2014), abrogation of its efflux could interfere with localized signaling
in response to DCF-induced injury. It should be noted that the inhibitor
concentrations chosen for the in vitroMRP4 inhibition assay were phys-
iologically relevant as they reflect the in vivo metabolite concentrations
observed in prior animal studies (Scialis et al., 2015; Manautou et al.,
2005; Chen et al., 2003; Scialis et al., 2019).
5. Conclusions
To summarize our findings, we report that Mrp4 mRNA expression was
induced after a single toxic dose of APAP, and that induction was maximal
at 12 h. ALT, as amarker of hepatic injury, was also elevated. Also, we show
that humanMRP4 function was inhibited by APAPmetabolites with APAP-
CYS achieving an apparent IC50 that is physiologically relevant. We believe
these findings demonstrate the intricate balance between compensatory
transporter upregulation due to xenobiotic intoxication and the possible
deleterious effects that xenobiotics continue to exert in the form of their cir-
culating metabolites.
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